Stock News•2 days ago
Iovance Biotherapeutics Q3 Earnings Call Highlights
Iovance Biotherapeutics reported record Q3 revenue of ~$122M, up 80% YoY, as AMTAGVI sales surpassed $100M in a quarter for the first time.
MarketLens
Has Iovance Biotherapeutics Turned a Corner with AMTAGVI
8 months ago
SHARE THIS ON:
Exclusive Content for Pro Members
Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.
SHARE THIS ON:
Related Articles
Has Carvana Truly Turned the Corner
8 months ago
Category
You may also like
Stock News•1 week ago
Iovance Reports Updated IOV-LUN-202 Results and Adds Precision TIL Strategy for Second-Line Metastatic Non-Small-Cell Lung Cancer (mNSCLC)
Iovance reported a 24.6% ORR in 69 non-squamous mNSCLC patients, consistent with prior results, and plans a 2027 sBLA for lifileucel. KRAS wild-type achieved 43.3% ORR versus 11.4% in KRAS-mutant dise...
Stock News•1 months ago
Iovance: Buy Now Before Many Growth Catalysts Kick In
Iovance raised 2026 revenue guidance to $410–$420 million as Amtagvi adoption accelerates, supported by expanding treatment access and faster manufacturing. Frontline melanoma and lung cancer trials p...
Breaking News
View All →Featured Articles
Top Headlines
Stock News•1 hour ago
GOOGL, GOOG IMPORTANT DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Alphabet Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - GOOGL, GOOG
Stock News•2 hours ago
Chinese exec was recruited to spy on Nvidia CEO, according to US intelligence memo
Stock News•5 hours ago
Older Nvidia Chips Just Cost Oracle Its Microsoft AI Deal
Stock News•6 hours ago
GOOGL, GOOG 重要截止日期：業內頂尖的律師事務所 ROSEN 鼓勵 Alphabet Inc. 投資者在向 GOOGL, GOOG 提出證券集體訴訟的重要截止日期之前聘請律師
Stock News•6 hours ago